Pfizer vaccine: trials show jab is ‘100 per cent effective and well tolerated’ among children aged 12 to 15

It was also announced the that first children in a trial assessing the effectiveness of the jab in youngsters aged six months to 11 years had been dosed

A new study suggests the Pfizer Covid-19 jab is “100 per cent effective and well tolerated” among children aged 12 to 15.

Pfizer said it now plans to seek approval for use of the vaccine in this age group from regulators around the world and hopes youngsters will start to receive the jab before the next school year.

Currently, only children at very high risk of severe infection are offered a jab.

Pfizer said the jab 'demonstrated 100 per cent efficacy and robust antibody responses' (Photo: Nick Potts/PA Wire)

Pfizer said the jab “demonstrated 100% efficacy and robust antibody responses exceeding those reported in trials of vaccinated 16-25-year-old participants in an earlier analysis”.

Read More
AstraZeneca efficacy: how effective is the Oxford vaccine - and how do Pfizer, M...

Albert Bourla, chief executive of Pfizer, said: “We plan to submit these data to FDA (the US Food and Drug Administration)… and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”

How was the research conducted?

Currently, only children at very high risk of severe infection are offered a jab (Photo: Nick Potts/PA Wire)

Researchers examined the use of the Pfizer/BioNTech vaccine in a trial of 2,260 teenagers in the US. Half were given the jab and the other half were given a placebo drug.

There were no Covid-19 cases seen in the group who received the vaccine and 18 infections among those who did not.

Participants in the Phase 3 trial showed “strong immunogenicity” a month after the second dose of the jab.

It added that “administration was well tolerated, with side effects generally consistent with those observed in participants 16 to 25 years of age”. All participants in the trial will be monitored for two years after their second dose.

Pfizer and BioNTech said they plan to submit the data for scientific peer review for potential publication.

The pharmaceutical company said it plans to submit the data to the UK regulator – the Medicines and Healthcare products Regulatory Agency – within the next couple of months.

Mr Bourla said: “We share the urgency to expand the authorisation of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.

Ugur Sahin, chief executive and co-founder of BioNTech, said: “Across the globe, we are longing for a normal life. This is especially true for our children.

“The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant.

“It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones.”

What other research is ongoing?

Meanwhile, the companies also announced they have dosed the first children in a trial assessing the safety and effectiveness of the jab in youngsters aged six months to 11 years.

And Oxford University is carrying out a clinical trial on children aged six to 17 to test the safety and efficacy of its vaccine in younger age groups, with initial results expected in the summer.

But Professor Adam Finn, of the Joint Committee on Vaccination and Immunisation, said on Wednesday that no final decisions have been made about vaccinating youngsters.

The news comes after figures showed a slight rise in cases among youngsters after schools reopened.

In its latest weekly surveillance report, published last week, Public Health England said the rate for 10 to 19-year-olds stood at 100.7 cases per 100,000 in the seven days to March 21.

This was the highest rate across all age groups and was up week-on-week from 79.7.

Additional reporting by Press Association